29 June 2021
Latham & Watkins Advises Zentalis Pharmaceuticals on Offering of Common Stock
Advising firms
Deal team
5 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Nathan Ajiashvili Lead | Latham & Watkins LLP | Partner | capital markets | New York |
| Cheston Larson Lead | Latham & Watkins LLP | Partner | capital markets | San Diego |
| Salvatore Vanchieri | Latham & Watkins LLP | Associate | capital markets | New York |
| Matthew DeSilva | Latham & Watkins LLP | Associate | capital markets | New York |
| Andrew Borruso | Latham & Watkins LLP | Associate | capital markets | New York |
2 more lawyers on this deal. Register free to see the full deal team, with seniority, practice and office.
REGISTER FREE SIGN INWant co-counsel patterns, repeat clients and alerts when these firms land their next deal? Get Pro.
Stated terms
- Stated value
- USD 48.5 (US$48.50 per share)
- What the figure measures
- Per share
- Client
- Zentalis Pharmaceuticals, Inc.Issuer
- Counterparties
- Not stated